122665-73-0

Usage

Uses

Used in Organic Synthesis:
CMDA is used as an alkylating agent for the synthesis of various organic compounds, facilitating the addition of alkyl groups to molecules by replacing hydrogen atoms.
Used in Pharmaceutical Research:
CMDA is used as a key component in the development of pharmaceutical drugs, particularly in the synthesis of compounds with potential therapeutic applications.
Used in Anti-Cancer Drug Production:
CMDA is used as an alkylating agent in the production of certain anti-cancer drugs, where its ability to disrupt cancer cell DNA leads to the destruction of these cells.
Used in the Treatment of Neurodegenerative Diseases:
CMDA is being studied for its potential use in treating diseases such as Parkinson's and Alzheimer's, where its alkylating properties may offer therapeutic benefits.

InChI:InChI=1/C17H23ClN2O8S/c1-29(26,27)28-11-10-20(9-8-18)13-4-2-12(3-5-13)16(23)19-14(17(24)25)6-7-15(21)22/h2-5,14H,6-11H2,1H3,(H,19,23)(H,21,22)(H,24,25)/t14-/m0/s1

Upstream product

• 123724-56-1 di-tert-butyl 4-<(2-chloroethyl)<2-(mesyloxy)ethyl>amino>benzoyl-L-glutamate 
• 76282-66-1 di-tert-butyl (S)-N-(p-aminobenzoyl)-glutamate 
• 88050-23-1 di-tert-butyl (S)-N-(p-nitrobenzoyl)-glutamate 
• 32677-01-3 L-glutamic acid di-tert-butyl ester hydrochloride 
• 123724-54-9 di-tert-butyl 4-benzoyl-L-glutamate 
• 122-04-3 4-nitro-benzoyl chloride 
• 16874-06-9 Glutamic acid di-tert-butyl ester 
• 130633-37-3 Di-tert-butyl 4-<(2-chloroethyl)(2-hydroxyethyl)amino>benzoyl-L-glutamate 
• 88050-23-1 Di-tert-butyl 4-nitrobenzoyl-L-glutamate 
• 130633-36-2 Di-tert-butyl 4-<(2-chloroethyl)amino>benzoyl-L-glutamate 
• 76282-66-1 Di-tert-butyl 4-aminobenzoyl-L-glutamate 
• 123724-56-1 Di-tert-butyl 4-<(2-chloroethyl)(2-mesyloxyethyl)amino>benzoyl-L-glutamate 

Downstream Products

• 122665-70-7 4-[(2-chloroethyl)-(2-mesyloxyethyl)amino]benzoic acid 
• 56-86-0 L-glutamic acid 

Relevant academic research and scientific papers

4-amino-fluorobenzamides and their use as cytotoxic prodrugs

The invention provides a compound which is a 3-fluorobenzamide of the formula (A) STR1 wherein R-NH is the residue of an α-amino acid R-NH2 or oligopeptide R-NH2, and M is a nitrogen mustard group of the formula STR2 wherein Y and L, which may be the same or different in a molecule, are leaving groups; or a pharmaceutically acceptable salt thereof. The compounds are useful as prodrugs for treating cancer.

Improvements relating to the production of prodrugs

The invention provides compounds of the formula XX: M-Ar-CONH-R, where Ar represents an aromatic ring system, R-NH is the residue of an α-amino acid R-NH2 or oligopeptide R-NH2 and contains at least one carboxylic acid group in the f

SYNTHESIS OF AN N-MUSTARD PRODRUG

We describe the synthesis of the novel N-mustard prodrug 4-benzoyl-L-glutamic acid, which is designed for activation by tumour localising antibody-carboxypeptidase conjugates.

Novel Prodrugs Which Are Activated to Cytotoxic Alkylating Agents by Carboxypeptidase G2

The synthesis of three novel prodrugs, 4-amino>benzoyl-L-glutamic acid (7), 4-amino>benzoyl-L-glutamic acid (8), and 4-benzoyl-L-glutamic acid (9), for use as anticancer ag